CLISEQ Ltd. is a translational diagnostics company spun out of the Weizmann Institute of Science, via its commercialization arm Yeda Research and Development Company Ltd., that is advancing minimally invasive diagnostic approaches for hematologic disorders. The company holds exclusive rights to a patented technology developed at the Weizmann Institute, which enables use of peripheral blood single-cell RNA sequencing (scRNA-seq) to detect conditions such as myelodysplastic syndromes (MDS) as an alternative to bone-marrow aspiration. In partnership with 10x Genomics, Inc. and the Weizmann Institute, CLISEQ is conducting an international multi-site clinical trial (PERIBLOOD) enrolling over 1,500 participants across several continents to validate the technology’s clinical utility and facilitate future diagnostics workflows in hematology.